StockNews.com Initiates Coverage on Can-Fite BioPharma (NYSE:CANF)

Equities researchers at StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note issued on Thursday. The firm set a “sell” rating on the stock.

Several other research analysts also recently weighed in on CANF. D. Boral Capital reissued a “buy” rating and issued a $10.00 target price on shares of Can-Fite BioPharma in a research report on Tuesday, February 18th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th.

Can-Fite BioPharma Price Performance

Can-Fite BioPharma stock opened at $1.76 on Thursday. The firm’s 50 day simple moving average is $1.57 and its 200-day simple moving average is $1.95. The company has a market cap of $6.23 million, a P/E ratio of -0.98 and a beta of 1.33. Can-Fite BioPharma has a fifty-two week low of $1.29 and a fifty-two week high of $4.69.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. BNP Paribas Financial Markets acquired a new stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned approximately 0.71% of Can-Fite BioPharma as of its most recent filing with the Securities & Exchange Commission. 21.00% of the stock is owned by hedge funds and other institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.